Gossamer Bio, Inc. (NASDAQ:GOSS) Sees Significant Increase in Short Interest

Gossamer Bio, Inc. (NASDAQ:GOSS) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 7,020,000 shares, a growth of 10.0% from the November 30th total of 6,380,000 shares. Based on an average daily volume of 1,290,000 shares, the short-interest ratio is currently 5.4 days.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Gossamer Bio in a research note on Monday, November 11th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Gossamer Bio currently has a consensus rating of “Buy” and an average price target of $9.20.

Hedge Funds Weigh In On Gossamer Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. US Bancorp DE acquired a new stake in Gossamer Bio during the 3rd quarter worth approximately $39,000. Choreo LLC purchased a new stake in shares of Gossamer Bio during the second quarter worth approximately $46,000. GSA Capital Partners LLP acquired a new stake in shares of Gossamer Bio during the third quarter worth $67,000. Algert Global LLC acquired a new position in Gossamer Bio in the 2nd quarter valued at $75,000. Finally, Sequoia Financial Advisors LLC raised its position in Gossamer Bio by 26.7% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company’s stock worth $117,000 after buying an additional 25,000 shares during the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Price Performance

Shares of NASDAQ GOSS opened at $0.88 on Tuesday. The stock has a market cap of $199.03 million, a P/E ratio of -2.74 and a beta of 1.85. Gossamer Bio has a twelve month low of $0.50 and a twelve month high of $1.60. The stock has a 50 day moving average of $0.81 and a two-hundred day moving average of $0.89. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The business had revenue of $9.48 million for the quarter, compared to analyst estimates of $4.52 million. On average, research analysts forecast that Gossamer Bio will post -0.28 earnings per share for the current year.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.